SOURCE: Amarillo Biosciences, Inc.

March 27, 2006 09:50 ET

Amarillo Biosciences Receives Notification That Cambodia Has Approved Registration of Company's Natural Human Low-Dose Oral Interferon

AMARILLO, TX -- (MARKET WIRE) -- March 27, 2006 -- Amarillo Biosciences, Inc. (ABI) (OTC BB: AMAR) today announced that it had received notification from its licensee Global Kinetics, Inc. that the Ministry of Health of the Royal Government of Cambodia had approved the registration of ABI's natural human low-dose interferon alpha, which will be marketed under the name VELDONA. The official notification, received by Global Kinetics from the Director-General of Technical Health, Dr. Tep Lun, also indicated that Global Kinetics must wait two to three weeks to obtain a provisional certificate allowing the importation of VELDONA for sale in the Kingdom of Cambodia. Global Kinetics has a license and supply agreement for interferon from ABI in the countries of Cambodia, Laos and Vietnam.

Global Kinetics' president Jerry Frasier said, "I am pleased that Global Kinetics received notification of approval from the Kingdom of Cambodia. This is a significant step in our effort to provide low-dose oral interferon to the part of the world's population that needs it the most. I feel that low-dose oral interferon will be useful as an immune system modulator, helping to effectively fight viral infections such as avian influenza."

ABI CEO Joseph Cummins said, "The receipt of this formal notification from the Kingdom of Cambodia is an important milestone for our company. We will immediately start the process of manufacturing VELDONA lozenges from interferon supplied to us by Hayashibara Biochemical Laboratories Inc., our longtime partner and shareholder. We expect our agreement with Global Kinetics to generate significant revenues over the course of this year. More important, we believe that this recent approval will accelerate our efforts to register VELDONA in other Southeast Asian countries."

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 16.2% of Amarillo Biosciences shares and has provided over $17.8 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, idiopathic pulmonary fibrosis, hepatitis B, myeloproliferative diseases and opportunistic infections in patients who are HIV positive. In its 20-year history, ABI has invested $37 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at

About Global Kinetics, Inc.

Global Kinetics Inc. is a privately owned Washington State based company with its primary focus on business in Southeast Asia. Global Kinetics is working to assist countries including Cambodia to improve its healthcare and other infrastructure making available advanced healthcare technologies and other technologies allowing these areas to be more productive in a competitive world market. Additional information regarding Global Kinetics, Inc. may be obtained from Jerry Frasier by email at

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2004.

Contact Information

  • Contact:

    Investor Relations:
    Philippe Niemetz
    PAN Consultants, Ltd.
    Tel: 800-477-7570
    Tel: 212-344-6464
    Fax: 212-618-1276

    Joseph M. Cummins, DVM, PhD
    Amarillo Biosciences, Inc.
    Tel: 806-376-1741 x 13
    Fax: 806-376-9301